论文部分内容阅读
目的：探讨恶性肿瘤介入治疗中动脉应用５－ＨＴ３受体拮抗剂对防治胃肠道副作用的价值。方法：采用随机对照研究，分为治疗组（ｎ＝１２０）和对照组（ｎ＝４０），治疗组再分为欧必亭组（ｎ＝６０）和非欧必亭组（ｎ＝６０），其中 ３０例为自身对照。治疗组术中化疗／栓塞前 １５分钟（ｎ＝６０）或后即刻（ｎ＝６０）于动脉内推注 ５－ＨＴ３受体拮抗剂，对照组术中来用 ５－ＨＴ３受体拮抗剂。主要采用 ５－ＦＵ、ＤＤＰ、ＭＭＣ、ＴＨＰ或 ＡＤＭ大剂量联合灌注化疗方案。结果：介入治疗术中急性胃肠道反应发生率为１４．４％（２３／１６０），其中治疗组为１４．２％（１７／１２０），对照组为１５． ０％（６／４０），两组差异无显著意义（Ｐ＞０．０５）；但５－ＨＴ３受体拮抗剂介入化疗／栓塞前应用组明显优于化疗／栓塞后应用组（Ｐ＜０．０５）。出现胃肠道反应后立即停止操作，治疗组仍动脉内推注５－ＨＴ３受体拮抗剂。症状缓解率对照组为６６．６％（４／６），治疗组达 １００％；两组差异有显著意义（Ｐ＜０，０５）。术后 １２小时、１天和３天胃肠道反应发生率对照组分别为４７．５％（１９／４０）、４５％（１８／４０）和３７．５％（１５／４０），治疗组分别为１．６％（２
Objective: To investigate the value of 5-HT3 receptor antagonist in the prevention and treatment of gastrointestinal side effects in the interventional treatment of malignant tumor. Methods: A randomized controlled study was divided into treatment group (n = 120) and control group (n = 40). The treatment group was divided into the group of Euripin group (n = 60) and non-Euripin group For their own control. In the treatment group, 5-HT3 receptor antagonists were injected intra-arterially 15 minutes prior to chemotherapy / embolization (n = 60) or immediately thereafter (n = 60), and 5-HT3 receptor antagonists were intraoperatively administered in the control group. The main use of 5-FU, DDP, MMC, THP or ADM bolus chemotherapy. Results: The incidence of acute gastrointestinal reaction in interventional therapy was 14.4% (23/160), of which 14.2% (17/120) in the treatment group and 15% in the control group. (P <0.05). However, the application of 5-HT3 receptor antagonist before chemotherapy / embolization group was significantly better than that of chemotherapy / embolization group (P <0 0%, 6/40) .05). Immediately after the onset of gastrointestinal reactions, the treatment group was still bolus 5-HT3 receptor antagonist. The rate of symptom relief was 66.6% (4/6) in the control group and 100% in the treatment group. There was significant difference between the two groups (P <0,05). The incidence of gastrointestinal reactions at 12 hours, 1 day and 3 days after operation were 47.5% (19/40), 45% (18/40) and 37.5% (15/40) in the control group, respectively Respectively 1.6% (2